Introduction
Methods
Data sources and searches
Eligibility criteria
Data synthesis and analysis
Results
Selection of studies
Mean annual growth rates from studies over time
Study | Objective, mm | Period | Participants | Mean age, years | Male,% | Morphology/therapy | Imaging | Mean follow-up, years | Mean growth rate, mm/yeara |
---|---|---|---|---|---|---|---|---|---|
Coady 1997 [2] | TAA > 35 | 1985–1996 | 16 | ND | ND | Chronic dissection | CT, MRI, TTE | 2.2 | 3.7 (1.3–6.1) |
63 | ND | ND | No dissection | 0.9 (0.3–1.5) | |||||
54 | ND | ND | Ascending aorta | 1.0 (0.4–1.6) | |||||
25 | ND | ND | Descending aorta | 2.0 (0.9–5.1) | |||||
Davies 2002 [3] | TAA > 35 | 1985–2000 | 129 | ND | ND | Chronic dissection | CT, MRI, TTE | 1.6 | 1.4 |
203 | ND | ND | No dissection | 0.9 | |||||
332b | ND | ND | Ascending aorta | 0.7 | |||||
ND | ND | Descending aorta | 1.9 | ||||||
La Canna 2006 [18] | aTAA 40–60 | 1992–2003 | 27 | 49 | 96 | BAV | TEE, TTE | 3.0 | 0.81 ± 1.1, ns |
86 | 61 | 80 | TAV | 3.3 | 0.75 ± 1.1, ns | ||||
Davies 2007 [11] | aTAA > 35 | 1985–2005 | 70 | 49 | 74 | BAV | CT, MRI, TTE | 3.6 | 1.9 (1.3–2.5)* |
451 | 64 | 63 | TAV | 3.5 | 1.3 (1.1–1.5)* | ||||
521 | ND | ND | Mixed AV/ | ND | 1.4 (1.2–1.6) | ||||
Etz 2010 [19] | BAV-TAA | 1988–2008 | 90 | ND | ND | BAV | CT, partly digitised | 4.2 | 0.77 |
Angeloni 2015 [20] | aTAA | 2005–2011 | 329c | 68 | 62 | Statin | TTE, added CT | 3 | 0.95 ± 0.44*** |
329c | 64 | 62 | No statin | 3 | 1.27 ± 0.56*** |
Study | Objective, mm | Period | Participants | Mean age, years | Male, % | AV type | Imaging | Mean FU, years | Mean growth rate, mm/yeara |
---|---|---|---|---|---|---|---|---|---|
Gagné-Loranger 2016 [21] | aTAA 40–50 | 2001–2015 | 251 | 65 | 71 | 22% BAV | CT-ce axial | 4.3 | 0.42 ± 0.82 |
Kim 2016 [22]b | aTAA 40–55 | 2001–2014 | 270 | – | – | BAV | TTE | 3.9 | 0.20(0.12–0.28)*** |
1144 | – | – | TAV | 0.08(0.04–0.12)*** | |||||
1414 | 66 | 80 | Mixed | 0.10(0.06–0.14) | |||||
Park 2017 [16] | aTAA ≥ 40 | 2003–2014 | 509 | 67 | 56 | 5% BAV | CT-ce axial | 4.3 | 0.3 ± 0.5 |
Trinh 2017 [23] | BAV-TAA | 2009–2014 | 20 | 45 | 80 | BAV | CE-MRA | 2.6 | 0.5 ± 0.8 |
Agnese 2019 [24] | aTAA > 2.1 cm/m2 | 2000–2017 | 41 | 57 | 83 | BAV | TTE | 4 | BAV vs TAV ns |
165 | 69 | 84 | TAV | ||||||
206 | – | – | Mixed | TTE | 4 | 0.46 ± 0.04 | |||
Rooprai 2019 [29] | BAV-TAA | 2014–2018 | 29 | 57 | 66 | BAV | TTE, CT, MRI | 2.9 | 0.75 ± 0.81 |
Adriaans 2021 [17] | aTAA > 40 | 1999–2019 | 57 | 52 | 67 | BAV | CT, MRI, TTE | 6.7 | 0.2 ± 0.3 ns |
275 | 66 | 76 | TAV | 0.2 ± 0.4 ns | |||||
332 | 64 | 75 | Mixed | 0.2 ± 0.4 | |||||
Van Hout 2021 [28] | TAA | ND | 31 | 55 | 74 | TAV | MRI | 8.0 | 0.39 ± 0.33 |
Korpela 2022 [25] | aTAA > 40 | 2017–2020 | 30 | 66 | 80 | TAV | 4D flow MRI | 1.0 | 0.9 |
Weininger 2022 [26] | aTAA > 40 | 2013–2016 | 207 | 74 | 84 | Mixed | CT-do | 2.7 | 0.13 (median, IQR 0.24–0.49) |
Gulati 2022 [27] | aTAA > 40 | – | 67 | 68 | 100 | 7% BAV | CT-do, 91% CTA | 4.1 | 0.11 ± 0.31 |
Kauhanen 2022 [30] | aTAA > 40 | 2013–2018 | 143 | 64 | 80 | 12% BAV | CTA, ECG-gt | 3.4 | 0.2 ± 0.5 |
Hiratzka 2023 [31] | aTAA 40–49 | 2015–2020 | 197 | 62 | 69 | 5% BAV | CT/MRI-oe | 2.9 | 0.022 (−0.01 to +0.04) |
Pace 2023 [32] | aTAA > 39 | 2002–2022 | 432 | ND | ND | ND | CT, 71% CTA, 44% ECG-gt | 4c | 0.1 (0.1–0.2) |
Growth rates in TAV versus BAV
Growth rates in relation to aneurysm size and follow-up duration
Study | Objective, mm | Participants | Mean follow-up, years | Baseline diameter, mm | Mean growth rate, mm/yeara |
---|---|---|---|---|---|
Coady 1997 [2] | aTAA, > 35 | 54 | 2.2 | 40 | 0.8 (0.3–1.2) |
50 | 1.0 (0.4–1.5) | ||||
60 | 1.1 (0.5–1.8) | ||||
70 | 1.3 (0.6–2.1) | ||||
80 | 1.5 (0.6–2.4) | ||||
Gagné-Loranger 2016 [21] | aTAA, 40–50 | 65 | 4.3 | 40–44 | 0.55 ± 0.77 |
186 | 45–50 | 0.38 ± 0.84 ns | |||
Park 2017 [16] | aTAA, ≥ 40 | 321 | 4.3 | 40–44 | 0.3 ± 0.5 |
142 | 45–49 | 0.3 ± 0.5 ns | |||
46 | ≥ 50 | 0.7 ± 0.9** | |||
Gulati 2022 [27] | aTAA, ≥ 40 | 46 | 4.1 | ≤ 45 | 0.09 ± 0.32 |
21 | > 45 | 0.14 ± 0.31 ns | |||
Pace 2023 [32] | aTAA, > 39 | 43 | 1.0b | < 40 | 0.2 (0.1–0.3) |
200 | 0.9b | 40–44 | 0.1 (0.1–0.2) | ||
130 | 0.7b | 45–49 | 0.1 (0.03–0.1) | ||
41 | 0.8b | 50–54 | 0.2 (0.1–0.3) | ||
12 | 0.9b | ≥ 55 | 1.9 (1.2–2.5)* |